Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy

Compare efficacy of gene therapy alone (monotherapy) or in combination with an SMN2 augmentation agent (dual therapy) for treatment of children at risk for spinal muscular atrophy type 1.